OncoPharm
OncoPharm
John Bossaer
ASH 2025
29 minutes Posted Dec 11, 2025 at 5:51 pm.
0:00
29:05
Download MP3
Show notes
ASH 2025 Highlights:
MajesTEC-3: Teclistamab + Daratumumab in relapse refractory Multiple Myeloma
Paradigm: HMA + Ven vs. 7+3 or CPX-351
Denosumab safety & dosing in Multiply Myeloma and renal dysfunction
Trilaciclib and CDK 4/6 inhibition as protection against TP53-mutated clonal hematopoiesis?